Skip to main content
NGL Fine Chem Ltd. logo

NGL Fine Chem Ltd. — Investor Relations & Filings

Ticker · NGLFINE ISIN · INE887E01022 LEI · 335800X5TUU2OAV19X07 BSE.NS Manufacturing
Open in API
Filings indexed 309 across all filing types
Latest filing 2022-08-11 Regulatory Filings
Country IN India
Listing BSE.NS NGLFINE

About NGL Fine Chem Ltd.

https://www.nglfinechem.com

NGL Fine Chem Ltd. specializes in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates for both veterinary and human healthcare sectors. The company focuses on high-quality chemical synthesis, producing a diverse range of products including anthelmintics, ectoparasiticides, and specialty chemicals. Key products in its portfolio include Nitroxynil, Closantel, Oxyclozanide, and Triclabendazole. Operating with Good Manufacturing Practice (GMP) standards, the firm serves a global clientele, providing customized manufacturing solutions and maintaining a strong emphasis on research and development to enhance process efficiency and product quality. Its technical expertise lies in complex chemical reactions and large-scale production of niche pharmaceutical components.

Recent filings

Filing Released Lang Actions
Related Party Transaction
Regulatory Filings Classification · 95% confidence The document is a disclosure of Related Party Transactions for the half year ended 31st March 2022, submitted to the National Stock Exchange of India. It references Regulation 23(9) of the SEBI Listing Obligations and Disclosure Requirements, which mandates such disclosures. The content includes detailed tables of related party transactions, values, and balances, indicating substantive financial data related to related party dealings. This type of document is a regulatory disclosure specific to related party transactions, which is typically classified under Regulatory Filings (RNS) as it does not fit into other more specific categories like Annual Report or Interim Report. It is not a full financial report but a compliance disclosure filing.
2022-08-11 English
General updates
Interim / Quarterly Report Classification · 95% confidence The document is a communication addressed to stock exchanges (BSE and NSE) regarding the resubmission of unaudited financial results for the quarter ended June 30, 2022. It mentions a correction of a typographical error in the previously submitted financial results and includes detailed unaudited consolidated and standalone financial results for the quarter ended June 30, 2022. The presence of detailed financial data for a quarter, including revenue, expenses, profit/loss, and earnings per share, indicates this is a quarterly financial report. The document is not a brief announcement or a certification but contains substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2022-08-11 English
Resignation
Board/Management Information Classification · 100% confidence The document text is a formal communication addressed to stock exchanges (BSE and NSE) regarding a change in the company's board of directors, specifically a resignation effective at the close of business on August 10, 2022. It includes details such as the reason for change (resignation), date of resignation, and notes on directorships and committee memberships. There is no financial data, report, or presentation content. This fits the category of announcements about changes in the company's board or senior management.
2022-08-10 English
Outcome of Board Meeting
Regulatory Filings
2022-08-10 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is a notification from NGL Fine-Chem Limited to stock exchanges about scheduling a conference call with investors and analysts to discuss the company's first quarter unaudited financial results for the quarter ended June 30, 2022. It includes details about the date, time, and dial-in information for the call. The document does not contain the actual financial results or detailed analysis but is an announcement of the upcoming earnings call event. Therefore, it fits the category of a Call Transcript (CT) announcement or more precisely an announcement of the call itself. However, since it is only the schedule and invitation for the conference call and not the transcript, the best fitting category is Regulatory Filings (RNS) as a general regulatory announcement about the call schedule, not the transcript or the earnings release itself.
2022-08-08 English
Loss of share certificate
Regulatory Filings Classification · 90% confidence The document contains a simple table listing shareholders with folio numbers, certificate numbers, distinctive numbers, and number of shares. There is no indication of financial data, management discussion, voting results, or any report content. The document is very short (236 characters) and appears to be a list of shareholders or shareholding details. This fits best with a Major Shareholding Notification (MRQ) or possibly a Transaction in Own Shares (POS), but since it is just a shareholder list without transaction details, it aligns more with Major Shareholding Notification. However, the document does not explicitly mention changes in share ownership or threshold crossing, so it is more likely a general shareholding list. Given the lack of explicit context, the fallback category Regulatory Filings (RNS) is appropriate for such miscellaneous filings that do not fit other categories.
2022-07-28 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.